Yue Li is an experienced analytical development scientist with a comprehensive background in quality assurance, research, and development within the biomedical field. Currently serving as an Analytical Development Scientist II at CTMC, a joint venture between Resilience and MD Anderson Cancer Center, since May 2022, Yue previously worked as an analytical development scientist at MD Anderson Cancer Center from March 2021 to April 2022. Additionally, experience includes a senior role in quality assurance and control at Baylor College of Medicine, serving as a research instructor at The University of Texas Health Science Center at Houston, and conducting significant research as a research investigator at MD Anderson Cancer Center. Yue has also held postdoctoral positions at UTHSCSA and UCLA, focusing on DNA repair and kinetoplast DNA replication proteins. Yue holds a Ph.D. in Pharmacology and a Master's in Molecular Biology from the Shanghai Institutes for Biological Sciences, as well as a Bachelor's degree in Biochemistry from Nanjing University.
This person is not in any offices
CTMC / A joint venture between Resilience + MD Anderson Cancer Center
Cell Therapy Manufacturing Center (CTMC) is a joint venture between Resilience and MD Anderson Cancer Center. CTMC was created to bring together the leading complex biologics manufacturing technology organization and the #1 clinical cancer center to enable innovation from academia and biotech to accelerate Cell Therapy’s impact for cancer patients.
Employees
51-200